Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

2015/04/15 by Gregory L. Beatty, Rafael Winograd, Rebecca A. Evans +10 · 290 citations
Chemistry · Immunology and Microbiology · Medicine · #Biology #CAR-T cell therapy research #CD40 #CD8 #Cancer #Cancer Immunotherapy and Biomarkers #Cancer research #Chemistry #Cytotoxic T cell #Gemcitabine #Immune system #Immunology #Immunotherapy and Immune Responses #Internal medicine #Medicine #Pancreatic cancer #T cell #Tumor microenvironment

paper · open access · doi:10.1053/j.gastro.2015.04.010

published in Gastroenterology 149(1), 201-210 (Elsevier BV)

openalex publication_date 2015/04/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Cited by

• CD40 Agonist Antibodies in Cancer Immunotherapy
• Extracellular matrix architecture promotes immunosuppressive microenvironments in pancreatic cancer
• Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer
• Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma
• CCR4 Blockade Diminishes Intratumoral Macrophage Recruitment and Augments Survival of Syngeneic Pancreatic Cancer-Bearing Mice
• IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. [europepmc]
• Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. [europepmc]
• CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. [europepmc]
• Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. [europepmc]
• Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. [europepmc]
• Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. [europepmc]
• Macrophages as Key Drivers of Cancer Progression and Metastasis. [europepmc]
• Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. [europepmc]
• Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. [europepmc]
• The Immune Revolution: A Case for Priming, Not Checkpoint. [europepmc]
• Understanding the tumor immune microenvironment (TIME) for effective therapy. [europepmc]
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. [europepmc]
• Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. [europepmc]
• The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. [europepmc]
• CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. [europepmc]
• A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression. [europepmc]
• Host tissue determinants of tumour immunity. [europepmc]
• Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. [europepmc]
• Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. [europepmc]
• Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. [europepmc]
• CAR T cells in solid tumors: challenges and opportunities. [europepmc]
• Chemokines and the immune response to cancer. [europepmc]
• Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. [europepmc]
• The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. [europepmc]
• Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. [europepmc]